^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | bortezomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3950 / 5 - Sensitizing oncogenic mutant p53-expressing non-small cell lung cancer to proteasome inhibitors
Published date:
03/15/2023
Excerpt:
In vivo mouse xenograft studies demonstrated that combination treatments of BTZ + venetoclax or BTZ + carboplatin (a standard of care chemotherapy for NSCLC) significantly attenuated oncogenic mutant p53-expressing tumor growth….Our data suggest that the preferential cytotoxicity of BTZ, and potentially other PIs, in oncogenic mutant p53-expressing NSCLC cells
